Clarissa Sowemimo-Coker CEO:  OCTP Achieves Milestone in Phase One Clinical Trial

Previous
Previous

OCT features on Research Talks with Alan Green

Next
Next

Oxford Cannabinoid Technologies "officially on the way" after first dosing